CN110114070A - 使用依维莫司(everolimus)、达托里昔布(dactolisib)或二者增强免疫反应的方法 - Google Patents

使用依维莫司(everolimus)、达托里昔布(dactolisib)或二者增强免疫反应的方法 Download PDF

Info

Publication number
CN110114070A
CN110114070A CN201780080148.2A CN201780080148A CN110114070A CN 110114070 A CN110114070 A CN 110114070A CN 201780080148 A CN201780080148 A CN 201780080148A CN 110114070 A CN110114070 A CN 110114070A
Authority
CN
China
Prior art keywords
pharmaceutically acceptable
acceptable salt
bez235
rad001
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780080148.2A
Other languages
English (en)
Chinese (zh)
Inventor
琼·曼尼克
梅洛迪·莫里斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN110114070A publication Critical patent/CN110114070A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201780080148.2A 2016-11-23 2017-11-22 使用依维莫司(everolimus)、达托里昔布(dactolisib)或二者增强免疫反应的方法 Pending CN110114070A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662425766P 2016-11-23 2016-11-23
US62/425,766 2016-11-23
US201762476160P 2017-03-24 2017-03-24
US62/476,160 2017-03-24
US201762576511P 2017-10-24 2017-10-24
US62/576,511 2017-10-24
PCT/IB2017/001579 WO2018096402A1 (en) 2016-11-23 2017-11-22 Methods of enhancing immune response with everolimus, dactolisib or both

Publications (1)

Publication Number Publication Date
CN110114070A true CN110114070A (zh) 2019-08-09

Family

ID=60957348

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780080148.2A Pending CN110114070A (zh) 2016-11-23 2017-11-22 使用依维莫司(everolimus)、达托里昔布(dactolisib)或二者增强免疫反应的方法

Country Status (12)

Country Link
US (3) US10441584B2 (2)
EP (1) EP3544608A1 (2)
JP (1) JP2020500930A (2)
KR (1) KR20190089005A (2)
CN (1) CN110114070A (2)
AU (1) AU2017363970A1 (2)
BR (1) BR112019010470A2 (2)
CA (1) CA3044355A1 (2)
IL (1) IL266750A (2)
MX (1) MX2019006090A (2)
TW (1) TW201825090A (2)
WO (1) WO2018096402A1 (2)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11083725B2 (en) 2014-10-24 2021-08-10 St. Jude Children's Research Hospital Coordinated metabolic reprogramming in response to productive viral infections
CN110114070A (zh) 2016-11-23 2019-08-09 诺华公司 使用依维莫司(everolimus)、达托里昔布(dactolisib)或二者增强免疫反应的方法
US10596165B2 (en) 2018-02-12 2020-03-24 resTORbio, Inc. Combination therapies
WO2020223154A1 (en) * 2019-05-01 2020-11-05 resTORbio, Inc. Methods of enhancing immune response

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103391780A (zh) * 2011-02-16 2013-11-13 诺瓦提斯公司 用于治疗神经变性疾病的治疗剂的组合物
WO2016064683A1 (en) * 2014-10-24 2016-04-28 St. Jude Children's Research Hospital Coordinated metabolic reprogramming in response to productive viral infections
CN105899232A (zh) * 2013-11-13 2016-08-24 诺华股份有限公司 用于增强免疫应答的mTOR抑制剂

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1028606A (en) 1912-06-04 Victor Talking Machine Co Sound-box for talking-machines.
US1000480A (en) 1909-05-19 1911-08-15 J G Brill Co Car-truck.
US1044158A (en) 1911-01-27 1912-11-12 Allen H Fetzer Trolley-wheel.
ZA737247B (en) 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US5472712A (en) 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5681585A (en) 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
CA2175215C (en) 1993-11-19 2008-06-03 Yat Sun Or Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
SK78196A3 (en) 1993-12-17 1997-02-05 Sandoz Ag Rapamycin demethoxy-derivatives, preparation method thereof and pharmaceutical agent containing them
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5741677A (en) 1995-06-07 1998-04-21 Geron Corporation Methods for measuring telomere length
US5985890A (en) 1995-06-09 1999-11-16 Novartis Ag Rapamycin derivatives
FR2736550B1 (fr) 1995-07-14 1998-07-24 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
AU735648B2 (en) 1996-07-12 2001-07-12 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
CA2230748C (en) 1997-03-14 2010-08-03 American Home Products Corporation Rapamycin formulations for oral administration
US6015815A (en) 1997-09-26 2000-01-18 Abbott Laboratories Tetrazole-containing rapamycin analogs with shortened half-lives
TW557297B (en) 1997-09-26 2003-10-11 Abbott Lab Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same
ME00189B (me) 1998-03-26 2011-02-10 Astellas Pharma Inc Preparati sa neprekidnim oslobađanjem
ATE264863T1 (de) 1999-08-24 2004-05-15 Ariad Gene Therapeutics Inc 28-epirapaloge
GB0008785D0 (en) 2000-04-10 2000-05-31 Novartis Ag Organic compounds
GB0123400D0 (en) 2001-09-28 2001-11-21 Novartis Ag Organic compounds
PT1478648E (pt) 2002-02-01 2014-07-15 Ariad Pharma Inc Compostos contendo fósforo e suas utilizações
US20030203027A1 (en) 2002-04-26 2003-10-30 Ethicon, Inc. Coating technique for deposition of drug substance on a substrate
US7075204B2 (en) 2003-08-06 2006-07-11 Honeywell International, Inc. Threaded inner sleeve for generator magnet
AR045957A1 (es) 2003-10-03 2005-11-16 Novartis Ag Composicion farmaceutica y combinacion
US7220755B2 (en) 2003-11-12 2007-05-22 Biosensors International Group, Ltd. 42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same
GB0419355D0 (en) 2004-08-31 2004-09-29 Novartis Ag Organic compounds
US8758816B2 (en) 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
DK1848431T3 (en) 2005-02-09 2016-04-18 Santen Pharmaceutical Co Ltd LIQUID FORMULATIONS FOR TREATMENT OF DISEASES OR CONDITIONS
BRPI0608573A2 (pt) 2005-03-08 2017-07-25 Lifecycle Pharma As Composição farmacêutica, e, método para a preparação de uma composição farmacêutica.
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
ES2563288T3 (es) 2006-03-23 2016-03-14 Santen Pharmaceutical Co., Ltd Rapamicina en dosis bajas para el tratamiento de enfermedades relacionadas con la permeabilidad vascular
US20100266590A1 (en) 2006-08-02 2010-10-21 Demetri George D Combination therapy
EP1902708A1 (de) 2006-09-25 2008-03-26 Losan Pharma GmbH Wirkstoff enthaltende stabilisierte feste Arzneimittelformen und Verfahren zu ihrer Herstellung
KR20140091718A (ko) 2006-11-20 2014-07-22 노파르티스 아게 2-메틸-2-［4-(3-메틸-2-옥소-8-퀴놀린-3-일-2,3-디히드로-이미다조［4,5-ｃ］퀴놀린-1-일)-페닐］-프로피오니트릴의 염 및 결정 형태
AU2008218806B2 (en) 2007-02-20 2011-12-01 Novartis Ag Imidazoquinolines as dual lipid kinase and mTOR inhibitors
PL2182948T3 (pl) 2007-07-24 2013-07-31 Novartis Ag Zastosowanie imidazochinolin do leczenia chorób EGFR-zależnych albo chorób wykazujących nabytą oporność wobec środków ukierunkowanych na członków rodziny EGFR
US20090082387A1 (en) 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched nvp-bez234
US20090088373A1 (en) 2007-09-28 2009-04-02 Gallo Richard L Use of compositions to enhance innate immune response
JP2011513391A (ja) 2008-03-05 2011-04-28 パナセア バイオテック リミテッド ミコフェノラートを含有する徐放性医薬組成物およびその方法
KR20100126553A (ko) 2008-03-26 2010-12-01 노파르티스 아게 Ｖｅｇｆ-유도성 혈관신생 과정의 유력한 조절제로서의 이미다조퀴놀린 및 피리미딘 유도체
CA2733203A1 (en) 2008-08-05 2010-02-11 Emory University Use of mtor inhibitors to enhance t cell immune responses
EP2331566B1 (en) 2008-08-26 2015-10-07 City of Hope Method and compositions for enhanced anti-tumor effector functioning of t cells
WO2010049481A1 (en) 2008-10-31 2010-05-06 Novartis Ag Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor
ES2645692T3 (es) 2008-11-11 2017-12-07 The Board Of Regents,The University Of Texas System Microcápsulas de rapamicina y su uso para el tratamiento del cáncer
US8323649B2 (en) 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
US9452227B2 (en) 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
EP2375897A4 (en) 2009-01-14 2013-05-15 Health Research Inc METHOD AND COMPOSITIONS USING MTOR-INHIBITORS FOR IMPROVING IMMUNE REACTIONS
US20100233733A1 (en) 2009-02-10 2010-09-16 Nodality, Inc., A Delaware Corporation Multiple mechanisms for modulation of the pi3 kinase pathway
CA2757979A1 (en) 2009-04-09 2010-10-14 Alkermes Pharma Ireland Limited Controlled-release clozapine compositions
BRPI1010655A2 (pt) 2009-04-10 2019-09-03 Qi Haiyan novos agentes antienvelhecimento e métodos para identificá-los
CN101862297B (zh) 2009-04-14 2012-07-25 上海医药工业研究院 一种非水溶性药物的缓释微丸、其缓释口腔崩解片及其制备方法
US20120114637A1 (en) 2009-05-04 2012-05-10 Santen Pharmaceutical Co., Ltd. Mtor pathway inhibitors for treating ocular disorders
JP2013504325A (ja) 2009-09-09 2013-02-07 アビラ セラピューティクス， インコーポレイテッド Ｐｉ３キナーゼインヒビターおよびその使用
CN102199152A (zh) 2010-03-25 2011-09-28 高大新 杂环咪唑类磷脂激酶抑制剂
US20130296316A1 (en) 2010-07-09 2013-11-07 Michael P. Pollastri Antiparasitic Agents Based On mTOR Inhibitors
AR083267A1 (es) 2010-10-04 2013-02-13 Novartis Ag Combinaciones farmaceuticas
WO2012075253A2 (en) 2010-12-03 2012-06-07 Novartis Ag Pharmaceutical compositions
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
EP2667874A4 (en) 2011-01-27 2014-07-30 Univ Princeton MTOR KINASE HEMMER AS ANTIVIRUS AGENT
CN102138903B (zh) 2011-03-17 2012-12-12 苏州特瑞药业有限公司 一种依维莫司固体口服药物组合物
EP2741747A1 (en) 2011-08-10 2014-06-18 Novartis Pharma AG JAK P13K/mTOR COMBINATION THERAPY
MX2014003873A (es) 2011-09-30 2014-05-28 Dana Farber Cancer Inst Inc Metodo para tratar el carcinoma mucoepidermoide.
ES2663744T3 (es) 2011-10-06 2018-04-16 Novartis Ag Composiciones farmacéuticas que comprenden 40-O-(2-hidroxi)etil-rapamicina
EP2638896A1 (en) 2012-03-14 2013-09-18 Bioneer A/S Cationic liposomal drug delivery system for specific targeting of human cd14+ monocytes in whole blood
RU2766608C2 (ru) 2012-04-11 2022-03-15 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез Химерные антигенные рецепторы, нацеленные на антиген созревания b-клеток
RU2014154009A (ru) 2012-06-06 2016-08-10 Новартис Аг Комбинация ингибитора 17-альфа-гидроксилазы (с17,20-лиазы) и специфического ингибитора pi-3k для лечения онкологического заболевания
US10799473B2 (en) 2013-03-04 2020-10-13 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Methods of inhibiting IGF-1R activation or downtream signalling thereof to reduce radiation-induced cellular senescence
TW201503912A (zh) 2013-03-19 2015-02-01 Novartis Ag 包含癌莫事（ｅｖｅｒｏｌｉｍｕｓ）之醫藥組合物
WO2014191128A1 (en) 2013-05-29 2014-12-04 Cellectis Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system
KR101582264B1 (ko) 2013-06-27 2016-01-04 삼성전자 주식회사 유기 박막용 조성물, 유기 박막 및 상기 유기 박막을 포함하는 전자 소자
US9033062B2 (en) * 2013-07-11 2015-05-19 Caterpillar Inc. Control system for a machine
SI3151672T1 (sl) 2014-06-06 2021-03-31 Bluebird Bio, Inc. Izboljšani T-celični sestavki
SG10201913782UA (en) 2014-07-21 2020-03-30 Novartis Ag Treatment of cancer using a cll-1 chimeric antigen receptor
US20170274014A1 (en) 2014-07-21 2017-09-28 Jennifer Brogdon Combinations of low, immune enhancing, doses of mtor inhibitors and cars
TWI719942B (zh) 2014-07-21 2021-03-01 瑞士商諾華公司 使用ｃｄ３３嵌合抗原受體治療癌症
BR112017001183A2 (pt) 2014-07-21 2017-11-28 Novartis Ag tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado
JP2017528433A (ja) 2014-07-21 2017-09-28 ノバルティス アーゲー 低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ
MX2017002205A (es) 2014-08-19 2017-08-21 Novartis Ag Receptor quimerico de antigeno (car) anti-cd123 para uso en el tratamiento de cancer.
WO2016079332A1 (en) 2014-11-21 2016-05-26 Technical University Of Denmark Gel formulations for improving immunotherapy
CA2986359A1 (en) 2015-05-20 2016-11-24 Novartis Ag Pharmaceutical combination of everolimus with dactolisib
CN110114070A (zh) 2016-11-23 2019-08-09 诺华公司 使用依维莫司(everolimus)、达托里昔布(dactolisib)或二者增强免疫反应的方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103391780A (zh) * 2011-02-16 2013-11-13 诺瓦提斯公司 用于治疗神经变性疾病的治疗剂的组合物
CN105899232A (zh) * 2013-11-13 2016-08-24 诺华股份有限公司 用于增强免疫应答的mTOR抑制剂
WO2016064683A1 (en) * 2014-10-24 2016-04-28 St. Jude Children's Research Hospital Coordinated metabolic reprogramming in response to productive viral infections

Also Published As

Publication number Publication date
US20180161319A1 (en) 2018-06-14
US20200054624A1 (en) 2020-02-20
EP3544608A1 (en) 2019-10-02
US20200061051A1 (en) 2020-02-27
TW201825090A (zh) 2018-07-16
US10441584B2 (en) 2019-10-15
IL266750A (en) 2019-07-31
US11045463B2 (en) 2021-06-29
JP2020500930A (ja) 2020-01-16
WO2018096402A1 (en) 2018-05-31
KR20190089005A (ko) 2019-07-29
AU2017363970A1 (en) 2019-06-20
MX2019006090A (es) 2019-08-21
US10993940B2 (en) 2021-05-04
BR112019010470A2 (pt) 2019-09-10
CA3044355A1 (en) 2018-05-31

Similar Documents

Publication Publication Date Title
US11045463B2 (en) Methods of enhancing immune response
US11123329B1 (en) Use of angiotensin II type 2 receptor agonist
TW201825097A (zh) 使用包含微脂伊立替康(irinotecan)及奧沙利鉑(oxaliplatin)之組合療法治療胃癌之方法
CA3083341C (en) Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions
TWI907406B (zh) 使用布魯頓氏酪胺酸激酶抑制劑來治療復發型多發性硬化症之方法
US20210030741A1 (en) Pharmaceutical combination of everolimus with dactolisib
KR20220148826A (ko) 브루톤 티로신 키나아제의 저해제를 이용하여 원발성 진행형 다발성 경화증을 치료하는 방법
CA2937504A1 (en) Pharmaceutical combinations comprising a pi3k inhibitor for the treatment of cancer
US12005050B2 (en) Methods for preventing or treating H. pylori infection
TW202533829A (zh) 用於治療anca相關性血管炎的因子b抑制劑
EA045669B1 (ru) Способы лечения поведенческих и психологических симптомов у пациентов с деменцией
HK40081689B (en) New use of angiotensin ii type 2 receptor agonist
HK40081689A (en) New use of angiotensin ii type 2 receptor agonist
Terabe et al. THU0129 The Effectiveness of Biologic Agents Concomitant with Tacrolimus in Rheumatoid Arthritis

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190809

WD01 Invention patent application deemed withdrawn after publication